Matt Miksic
Stock Analyst at Barclays
(3.65)
# 720
Out of 5,182 analysts
338
Total ratings
53.99%
Success rate
3.77%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Overweight | $118 → $120 | $86.08 | +39.41% | 26 | Apr 1, 2026 | |
| MMED Minimed Group | Initiates: Overweight | $26 | $14.10 | +84.40% | 1 | Apr 1, 2026 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $217 → $234 | $243.45 | -3.88% | 16 | Mar 19, 2026 | |
| COO The Cooper Companies | Maintains: Overweight | $98 → $103 | $70.12 | +46.89% | 3 | Mar 6, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $63.87 | +14.29% | 10 | Feb 27, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $86 → $90 | $74.85 | +20.24% | 11 | Feb 26, 2026 | |
| GMED Globus Medical | Maintains: Overweight | $118 → $123 | $87.96 | +39.84% | 17 | Feb 25, 2026 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $20 | $16.53 | +20.99% | 7 | Feb 19, 2026 | |
| DXCM DexCom | Maintains: Underweight | $71 → $72 | $61.61 | +16.86% | 10 | Feb 13, 2026 | |
| BAX Baxter International | Maintains: Overweight | $30 → $25 | $16.62 | +50.42% | 24 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $104 → $100 | $91.02 | +9.87% | 10 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $202 | $155.40 | +29.99% | 2 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $87 | $69.95 | +24.37% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $124 | $62.97 | +96.92% | 20 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $169 → $142 | $102.66 | +38.33% | 32 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $686 → $712 | $452.08 | +57.49% | 9 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $80.22 | +29.64% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $204.14 | +34.22% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $4.31 | +178.75% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $10.88 | +148.16% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $18.37 | +199.40% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $6.84 | +353.22% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $329.74 | +37.38% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $0.65 | +441.29% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.75 | +52.78% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.39 | +308.54% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $73.45 | +36.15% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $169.84 | +146.11% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $14.83 | +88.81% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.58 | +478.58% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $9.54 | +811.95% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.23 | +1,023.60% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $10.08 | +138.21% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $3.90 | +130.77% | 1 | Dec 12, 2016 |
Medtronic
Apr 1, 2026
Maintains: Overweight
Price Target: $118 → $120
Current: $86.08
Upside: +39.41%
Minimed Group
Apr 1, 2026
Initiates: Overweight
Price Target: $26
Current: $14.10
Upside: +84.40%
Johnson & Johnson
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $217 → $234
Current: $243.45
Upside: -3.88%
The Cooper Companies
Mar 6, 2026
Maintains: Overweight
Price Target: $98 → $103
Current: $70.12
Upside: +46.89%
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $63.87
Upside: +14.29%
Alcon
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $74.85
Upside: +20.24%
Globus Medical
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $87.96
Upside: +39.84%
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $16.53
Upside: +20.99%
DexCom
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $61.61
Upside: +16.86%
Baxter International
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $16.62
Upside: +50.42%
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $91.02
Upside: +9.87%
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $155.40
Upside: +29.99%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $69.95
Upside: +24.37%
Feb 3, 2026
Maintains: Overweight
Price Target: $136 → $124
Current: $62.97
Upside: +96.92%
Feb 2, 2026
Maintains: Overweight
Price Target: $169 → $142
Current: $102.66
Upside: +38.33%
Jan 26, 2026
Maintains: Overweight
Price Target: $686 → $712
Current: $452.08
Upside: +57.49%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $80.22
Upside: +29.64%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $204.14
Upside: +34.22%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.31
Upside: +178.75%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $10.88
Upside: +148.16%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $18.37
Upside: +199.40%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.84
Upside: +353.22%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $329.74
Upside: +37.38%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $0.65
Upside: +441.29%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.75
Upside: +52.78%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.39
Upside: +308.54%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $73.45
Upside: +36.15%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $169.84
Upside: +146.11%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $14.83
Upside: +88.81%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.58
Upside: +478.58%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $9.54
Upside: +811.95%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.23
Upside: +1,023.60%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $10.08
Upside: +138.21%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $3.90
Upside: +130.77%